Division of Millendo Therapeutics Inc.
Latest From OvaScience Inc.
2018 was a banner year for venture funding, and Relay's December Series C was only the third largest VC round of the year. Other year-end financings include Millendo, Erasca, Aristea and more...
OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.
Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.
Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.
- Therapeutic Areas
- Gynecological, Urological
- North America
- Parent & Subsidiaries
- Millendo Therapeutics Inc.
- Senior Management
Christopher Kroegner, MD, CEO
Johnathan Gillis, VP, Finance
Ravi Mehrotra, PhD, Chief Corp. Dev. Officer
James D Luterman, PhD, EVP, R&D
- Contact Info
Phone: (617) 500-2802
215 First St.
Cambridge, MA 02142
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.